The FDA has recently approved Clarinex-D 24 Hour (desloratadine 5 mg and pseudoephedrine sulfate USP 240 mg) extended release tablets to treat nasal and non-nasal symptoms of seasonal allergic rhinitis in patients 12 years of age or older. There were two 2-week trials, both demonstrating significantly greater efficacy of Clarinex-D 24 Hour for allergic rhinitis, compared to desloratidine or pseudoephedrine, which led to FDA approval of this combination 24-hour medication. Clarinex-D 24 Hour also provided significantly greater relief from nasal congestion compared to desloratadine.
IN A MOVE to block generic over-the-counter (OTC) competition for its $3.2 billion antihistamine Claritin (loratadine) and lock-in sales of Clarinex (desloratadine), a newly launched successor, Schering-Plough Corp. (SHP) has filed separate suits against divisions of Johnson & Johnson (J&J) and American Home Products Corp. (AHP).
The FDA has recently approved Clarinex-D 24 Hour (desloratadine 5 mg and pseudoephedrine sulfate USP 240 mg) extended release tablets to treat nasal and non-nasal symptoms of seasonal allergic rhinitis in patients 12 years of age or older. There were two 2-week trials, both demonstrating significantly greater efficacy of Clarinex-D 24 Hour for allergic rhinitis, compared to desloratidine or pseudoephedrine, which led to FDA approval of this combination 24-hour medication. Clarinex-D 24 Hour also provided significantly greater relief from nasal congestion compared to desloratadine.
|
